Kilitch Drugs FY26 Net Profit Rises to ₹2,950.03 Lakhs
Kilitch Drugs (India) Limited announced its audited financial results for FY26 and Q4FY26, reporting a consolidated net profit of ₹2,950.03 lakhs for the full year, up from ₹2,494.01 lakhs in FY25. Q4FY26 net profit stood at ₹1,488.28 lakhs, driven by a surge in total income from operations to ₹8,960.27 lakhs. The company also issued bonus shares in a 1:1 ratio during the quarter, increasing its paid-up equity share capital to ₹3,496.16 lakhs.
*this image is generated using AI for illustrative purposes only.
Kilitch Drugs (India) Limited has reported its audited financial results for the quarter and year ended 31st March, 2026. The company's consolidated net profit after tax for FY26 rose to ₹2,950.03 lakhs, compared to ₹2,494.01 lakhs in the previous fiscal year. For the fourth quarter (Q4FY26), the consolidated net profit stood at ₹1,488.28 lakhs, an increase from ₹1,021.86 lakhs in the corresponding quarter of the previous year.
Consolidated Financial Performance
The company's consolidated total income from operations for Q4FY26 surged to ₹8,960.27 lakhs from ₹6,122.58 lakhs year-on-year. For the full year FY26, consolidated total income from operations grew to ₹23,547.49 lakhs from ₹19,831.85 lakhs in FY25. Profit before tax for Q4FY26 was recorded at ₹2,021.05 lakhs, compared to ₹1,384.38 lakhs in Q4FY25. Total comprehensive income for the quarter came in at ₹1,167.11 lakhs against ₹928.46 lakhs in the year-ago period.
| Metric: | Q4FY26 (Audited) | Q4FY25 (Audited) | FY26 (Audited) | FY25 (Audited) |
|---|---|---|---|---|
| Total Income from Operations: | ₹8,960.27 lakhs | ₹6,122.58 lakhs | ₹23,547.49 lakhs | ₹19,831.85 lakhs |
| Profit Before Tax: | ₹2,021.05 lakhs | ₹1,384.38 lakhs | ₹3,865.44 lakhs | ₹3,447.42 lakhs |
| Net Profit After Tax: | ₹1,488.28 lakhs | ₹1,021.86 lakhs | ₹2,950.03 lakhs | ₹2,494.01 lakhs |
| Total Comprehensive Income: | ₹1,167.11 lakhs | ₹928.46 lakhs | ₹2,843.53 lakhs | ₹2,380.33 lakhs |
| Basic & Diluted EPS (₹): | ₹4.24 | ₹6.47 | ₹8.91 | ₹16.60 |
Standalone and Capital Structure Updates
On a standalone basis, income from operations for Q4FY26 was ₹7,196.88 lakhs, up from ₹5,630.41 lakhs in Q4FY25. Standalone profit after tax for the quarter stood at ₹1,399.90 lakhs compared to ₹1,137.41 lakhs year-on-year. For the full year FY26, standalone income from operations rose to ₹18,857.43 lakhs, while standalone profit after tax grew to ₹3,239.96 lakhs.
During the quarter ended 31st March, 2026, the company issued 1,74,80,782 fully paid-up equity shares of face value ₹10 each as bonus shares in the ratio of 1:1. Consequently, the paid-up equity share capital as of 31st March, 2026, increased to ₹3,496.16 lakhs from ₹1,608.23 lakhs in the previous year. Reserves (excluding revaluation reserves) were reported at ₹24,469.17 lakhs on a consolidated basis.
Regulatory Compliance
The audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 15th May, 2026. The statutory auditors issued an unmodified opinion on the financial statements. The results were filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
With capital work-in-progress surging to ₹14,001.93 lakhs, what new manufacturing capacities or product segments is Kilitch Drugs targeting, and when are these facilities expected to become operational?
Given that the foreign subsidiary Kilitch Estro Biotech PLC posted a full-year net loss of ₹201.84 lakhs despite quarterly profitability, what strategic measures is the company taking to turn around its international operations?
How does Kilitch Drugs plan to manage its rising debt burden, with non-current borrowings nearly doubling to ₹5,860.35 lakhs, while sustaining the capital expenditure cycle without straining future cash flows?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
